Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 13
2003 9
2004 11
2005 6
2006 6
2007 20
2008 18
2009 18
2010 23
2011 18
2012 25
2013 28
2014 22
2015 21
2016 18
2017 31
2018 34
2019 44
2020 37
2021 36
2022 37
2023 29
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

441 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study.
Zanghì A, Borriello G, Bonavita S, Fantozzi R, Signoriello E, Barone S, Abbadessa G, Cellerino M, Ziccone V, Miele G, Lus G, Valentino P, Bucello S, Inglese M, Centonze D, Avolio C, D'Amico E. Zanghì A, et al. Among authors: centonze d. J Neurol. 2024 May 4. doi: 10.1007/s00415-024-12360-x. Online ahead of print. J Neurol. 2024. PMID: 38704488
Low-contrast visual acuity test is associated with central inflammation and predicts disability development in newly diagnosed multiple sclerosis patients.
Dolcetti E, Buttari F, Bruno A, Azzolini F, Gilio L, Di Caprio V, Lauritano G, Borrelli A, Galifi G, Furlan R, Finardi A, Musella A, Guadalupi L, Mandolesi G, Rovella V, Centonze D, Stampanoni Bassi M. Dolcetti E, et al. Among authors: centonze d. Front Neurol. 2024 Feb 23;15:1326506. doi: 10.3389/fneur.2024.1326506. eCollection 2024. Front Neurol. 2024. PMID: 38585351 Free PMC article.
Pharmacological blockade of 2-AG degradation ameliorates clinical, neuroinflammatory and synaptic alterations in experimental autoimmune encephalomyelitis.
Guadalupi L, Mandolesi G, Vanni V, Balletta S, Caioli S, Pavlovic A, De Vito F, Fresegna D, Sanna K, Vitiello L, Nencini M, Tartacca A, Mariani F, Rovella V, Schippling S, Ruf I, Collin L, Centonze D, Musella A. Guadalupi L, et al. Among authors: centonze d. Neuropharmacology. 2024 Jul 1;252:109940. doi: 10.1016/j.neuropharm.2024.109940. Epub 2024 Apr 2. Neuropharmacology. 2024. PMID: 38570068 Free article.
Human expressive movements: The boundary between health and disease from a contaminated perspective.
Pascarella A, Gasparini S, Bellia A, Bertolotti E, Bessi B, Cantalupo G, Centonze D, Cianci V, Cornaggia CM, Costabile F, Gambardella A, Labate A, Malacrino C, Magaudda A, Mula M, Paladin F, Pizza G, Tassinari CA, Vermiglio E, Ferlazzo E, Aguglia U. Pascarella A, et al. Among authors: centonze d. Neurosci Biobehav Rev. 2024 Mar 28;161:105639. doi: 10.1016/j.neubiorev.2024.105639. Online ahead of print. Neurosci Biobehav Rev. 2024. PMID: 38552759 Free article. Review. No abstract available.
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop).
Schiavetti I, Signori A, Albanese A, Frau J, Cocco E, Lorefice L, di Lemme S, Fantozzi R, Centonze D, Landi D, Marfia G, Signoriello E, Lus G, Zecca C, Gobbi C, Iodice R, Malimpensa L, Cordioli C, Ferraro D, Ruscica F, Pasquali L, Repice A, Immovilli P, Ferrò MT, Bonavita S, Di Filippo M, Abbadessa G, Govone F, Sormani MP; CladStop study group. Schiavetti I, et al. Among authors: centonze d. Eur J Neurol. 2024 Mar 28:e16250. doi: 10.1111/ene.16250. Online ahead of print. Eur J Neurol. 2024. PMID: 38549186
Mood disturbances in newly diagnosed Parkinson's Disease patients reflect intrathecal inflammation.
Stampanoni Bassi M, Gilio L, Galifi G, Buttari F, Dolcetti E, Bruno A, Belli L, Modugno N, Furlan R, Finardi A, Mandolesi G, Musella A, Centonze D, Olivola E. Stampanoni Bassi M, et al. Among authors: centonze d. Parkinsonism Relat Disord. 2024 May;122:106071. doi: 10.1016/j.parkreldis.2024.106071. Epub 2024 Feb 28. Parkinsonism Relat Disord. 2024. PMID: 38432021 Free article.
Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience.
Ruggieri S, Ianniello A, Copetti M, Altieri M, Buscarinu MC, Centonze D, Cortese A, De Giglio L, Fantozzi R, Gasperini C, Grimaldi LME, Landi D, Marfia GA, Mirabella M, Nistri R, Nociti V, Oddo O, Romano S, Salemi G, Tortorella C, Pozzilli C, Petracca M. Ruggieri S, et al. Among authors: centonze d. Neurotherapeutics. 2024 Feb 26;21(3):e00338. doi: 10.1016/j.neurot.2024.e00338. Online ahead of print. Neurotherapeutics. 2024. PMID: 38413275 Free article.
The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT).
Bianchi A, Matranga D, Patti F, Maniscalco L, Pilotto S, Di Filippo M, Zaffaroni M, Annovazzi P, Bertolotto A, Gasperini C, Quartuccio E, Centonze D, Fantozzi R, Gajofatto A, Gobbin F, Landi D, Granella F, Buccafusca M, Marfia GA, Chisari C, Naldi P, Bergamaschi R, Greco G, Zarbo IR, Rizzo V, Ulivelli M, Bezzini D, Florio L, Turazzini M, Di Gregorio M, Pugliatti M, Salemi G, Ragonese P; the MS-MigIT Study Group. Bianchi A, et al. Among authors: centonze d. J Neurol. 2024 May;271(5):2182-2194. doi: 10.1007/s00415-024-12214-6. Epub 2024 Feb 16. J Neurol. 2024. PMID: 38366072 Free PMC article.
441 results